Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Drugs
Erschienen in: Drugs 6/2013

01.05.2013 | Adis Drug Evaluation

Insulin Degludec and Insulin Degludec/Insulin Aspart: A Review of Their Use in the Management of Diabetes Mellitus

verfasst von: Gillian M. Keating

Erschienen in: Drugs | Ausgabe 6/2013

Einloggen, um Zugang zu erhalten

Abstract

Insulin degludec (Tresiba®) is an ultra-long-acting insulin analogue that is also available as a coformulation with rapid-acting insulin aspart (insulin degludec/insulin aspart) [Ryzodeg®]. Insulin degludec has a flat, stable glucose-lowering profile with a duration of action of >42 h, and less within-patient day-to-day variability in glucose-lowering effect than the long-acting insulin analogue insulin glargine. In clinical trials, insulin degludec achieved similar glycaemic control to that seen with insulin glargine in patients with type 1 or 2 diabetes, but with a lower risk of nocturnal hypoglycaemia. In addition, trials examining a flexible dosing regimen of insulin degludec in patients with type 1 or 2 diabetes show the potential for adjusting the injection time, without compromising glycaemic control or safety. A 200 U/mL formulation of insulin degludec is also available for use in patients who require large volumes of basal insulin. Insulin degludec/insulin aspart was noninferior to the long-acting insulin analogue insulin detemir in patients with type 1 diabetes and has the potential to reduce the number of daily injections. Trial results also indicate that insulin degludec/insulin aspart may be an appropriate option for initiating insulin therapy in patients with type 2 diabetes inadequately controlled with oral antidiabetic drugs. Subcutaneous insulin degludec was generally well tolerated in patients with type 1 or 2 diabetes. In conclusion, insulin degludec and insulin degludec/insulin aspart represent a useful advance in the treatment of type 1 or 2 diabetes.
Literatur
1.
Skyler JS, Bergenstal R, Bonow RO, et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care. 2009;32(1):187–92.PubMedCrossRef
2.
American Diabetes Association. Standard of medical care in diabetes: 2013. Diabetes Care. 2013;36(Suppl 1):S11–66.CrossRef
3.
Heise T, Pieber TR. Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies. Diabetes Obes Metab. 2007;9(5):648–59.PubMedCrossRef
4.
Arnolds S, Kuglin B, Kapitza C, et al. How pharmacokinetic and pharmacodynamic principles pave the way for optimal basal insulin therapy in type 2 diabetes. Int J Clin Pract. 2010;64(10):1415–24.PubMedCrossRef
5.
Peterson GE. Intermediate and long-acting insulins: a review of NPH insulin, insulin glargine and insulin detemir. Curr Med Res Opin. 2006;22(12):2613–9.PubMedCrossRef
6.
Ashwell SG, Gebbie J, Home PD. Twice-daily compared with once-daily insulin glargine in people with type 1 diabetes using meal-time insulin aspart. Diabet Med. 2006;23(8):879–86.PubMedCrossRef
7.
8.
9.
Jonassen IB, Havelund S, Ribel U, et al. Insulin degludec is a new-generation ultra-long acting basal insulin with a unique mechanism of protraction based on multi-hexamer formation [abstract no. 39-OR]. 70th Annual Scientific Sessions of the American Diabetes Association; Orlando, FL; 25–29 June 2010.
10.
Kurtzhals P, Heise T, Strauss HM, et al. Multi-hexamer formation is the underlying basis for the ultra-long glucose-lowering effect of insulin degludec [abstract no. 1049]. Diabetologia. 2011;54(Suppl 1):S426.
11.
Seested T, Havelund S, Jonassen IB, et al. Ultrastructural visualisation of insulin degludec multi-hexamers in the subcutaneous depot in vivo supports a unique mechanism of protraction [abstract no. 980-P]. Diabetes. 2012;61(Suppl 1):A250.
12.
Jonassen I, Hoeg-Jensen T, Havelund S, et al. Ultra-long acting insulin degludec can be combined with rapid-acting insulin aspart in a soluble co-formulation [abstract no 380]. J Pept Sci. 2010;16(Suppl 1):32.
13.
Nishimura E, Sørensen AR, Hansen BF, et al. Insulin degludec: a new ultra-long, basal insulin designed to maintain full metabolic effect while minimizing mitogenic potential [abstract no. 974]. Diabetologia. 2010;53(Suppl 1):S388–9.
14.
Nosek L, Coester H-V, Thomsen HF, et al. Glucose-lowering effect of insulin degludec is independent of subcutaneous injection region [abstract no. 899-P]. Diabetes. 2012;61(Suppl 1):A228.
15.
Korsatko S, Deller S, Zahiragic S, et al. Ultra-long-acting insulin degludec: two different formulations (U100 and U200) are bioequivalent and show similar pharmacodynamics [abstract no. 2349-PO]. Diabetes. 2011;60 Suppl:A624.
16.
Hövelmann U, Heise T, Nosek L, et al. Insulin degludec 200 U/ml is ultra-long-acting and has a flat and stable glucose-lowering effect [abstract no. 912]. Diabetologia. 2012;55(Suppl 1):S374–5.
17.
Heise T, Nosek L, Bøttcher SG, et al. Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes. Diabetes Obes Metab. 2012;14(10):944–50.PubMedCrossRef
18.
Nasrallah SN, Reynolds LR. Insulin degludec, the new generation basal insulin or just another basal insulin? Clin Med Insights Endocrinol Diabetes. 2012;5:31–7.PubMedCrossRef
19.
Steensgaard DB, Schluckebier G, Strauss HM, et al. Ligand-controlled assembly of hexamers, dihexamers, and linear multihexamer structures by the engineered acylated insulin degludec. Biochemistry (Moscow). 2013;52(2):295–309.CrossRef
20.
Jonassen I, Havelund S, Hoeg-Jensen T, et al. Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin. Pharm Res. 2012;29(8):2104–14.PubMedCrossRef
21.
Robinson JD, Neumiller JJ, Campbell RK. Can a new ultra-long acting insulin analog improve patient care? Investigating the potential role of insulin degludec. Drugs. 2012;72(18):2319–25.PubMedCrossRef
22.
Hirsch IB, Bode B, Courreges J-P, et al. Insulin degludec/insulin aspart administered once daily at any meal, with insulin aspart at other meals versus a standard basal-bolus regimen in patients with type 1 diabetes: a 26-week, phase 3, randomized, open-label, treat-to-target trial. Diabetes Care. 2012;35(11):2174–81.PubMedCrossRef
23.
24.
Heise T, Hermanski L, Nosek L, et al. Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabetes Obes Metab. 2012;14(9):859–64.PubMedCrossRef
25.
Reynolds NA, Wagstaff AJ. Insulin aspart: a review of its use in the management of type 1 or 2 diabetes mellitus. Drugs. 2004;64(17):1957–74.PubMedCrossRef
26.
Heise T, Hövelmann U, Nosek L, et al. Insulin degludec: two-fold longer half-life and a more consistent pharmacokinetic profile than insulin glargine [abstract no. 1046]. Diabetologia. 2011;54(Suppl 1):S425.
27.
Haahr HL, Arold G, Bottcher SG, et al. Insulin degludec has similar pharmacokinetic properties in subjects with renal impairment and subjects with normal renal function [abstract no. 923]. Diabetologia. 2012;55(Suppl 1):S379.
28.
Arold G, Kupčová V, Thrane M, et al. Insulin degludec has similar pharmacokinetic properties in subjects with hepatic impairment when compared to subjects with normal hepatic function [abstract no. 1119-P]. Diabetes. 2012;61 Suppl:A289.
29.
Danne T, Biester T, Blaesig S, et al. Ultra-long pharmacokinetic properties of insulin degludec in adults with type 1 diabetes is preserved in children and adolescents after single-dose administration [abstract no. 1047]. Diabetologia. 2011;54(Suppl 1):S425–6.
30.
Korsatko S, Deller S, Mader J, et al. Ultra-long pharmacokinetic properties of insulin degludec in younger adults are preserved in geriatric subjects with type 1 diabetes [abstract no. 924]. Diabetologia. 2012;55(Suppl 1):S379–80.
31.
Hompesch M, Morrow L, Watkins E, et al. Insulin degludec provides similar pharmacokinetic and pharmacodynamic responses in Black, White and Hispanic/Latino patients with type 2 diabetes [abstract no. 925]. Diabetologia. 2012;55(Suppl 1):S380.
32.
33.
Bergenstal R, Bhargava A, Jain R, et al. 200 U/mL insulin degludec improves glycemic control similar to insulin glargine with a low risk of hypoglycemia in insulin-naïve people with type 2 diabetes [abstract no. 207]. American Association of Clinical Endocrinologists 21st Annual Scientific and Clinical Congress; Philadelphia, PA; 23–27 May 2012.
34.
Birkeland KI, Home PD, Wendisch U, et al. Insulin degludec in type 1 diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine. Diabetes Care. 2011;34(3):661–5.PubMedCrossRef
35.
Zinman B, Fulcher G, Rao PV, et al. Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial. Lancet. 2011;377(9769):924–31.PubMedCrossRef
36.
Heller S, Buse J, Fisher M, et al. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet. 2012;379(9825):1489–97.PubMedCrossRef
37.
Mathieu C, Hollander P, Miranda-Palma B, et al. Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension. J Clin Endocrinol Metab. 2013;98(3):1154–62.PubMedCrossRef
38.
Onishi Y, Park SW, Yoo SJ, et al. Insulin degludec improves glycemic control in insulin-naïve patients with type 2 diabetes: results of a randomized pan-Asian trial [abstract no. 1059-P]. Diabetes. 2012;61(Suppl 1):A272.
39.
Zinman B, Philis-Tsimikas A, Cariou B, et al. Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long). Diabetes Care. 2012;35(12):2464–71.PubMedCrossRef
40.
Garber AJ, King AB, Del Prato S, et al. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet. 2012;379(9825):1498–507.PubMedCrossRef
41.
Philis-Tsimikas A, Del Prato S, Satman I, et al. Insulin degludec is superior to sitagliptin in improving glycaemic control in uncontrolled patients with type 2 diabetes on oral agents [abstract no. 40]. Diabetologia. 2012;55(Suppl 1):S22.
42.
Meneghini L, Atkin SL, Gough SC, et al. The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in people with type 2 diabetes. Diabetes Care. 2013;36(4):858–64.PubMedCrossRef
43.
Rodbard HW, Handelsman Y, Cariou B, et al. Insulin degludec reduces hypoglycemia and improves health status vs. insulin glargine in insulin-naïve type 2 diabetes [abstract no. 1192-P]. Diabetes. 2012;61(Suppl 1):A307–8.
44.
Rodbard HW, Zinman B, Cariou B, et al. Reduced nocturnal hypoglycaemia with insulin degludec as compared to insulin glargine: results of a 2-year randomised trial in type 2 diabetes [abstract no. 920]. Diabetologia. 2012;55(Suppl 1):S378.
45.
Novo Nordisk. Comparison of NN1250 with sitagliptin in subjects with type 2 diabetes never treated with insulin [ClinicalTrials.gov identifier NCT01046110]. US National Institutes of Health, ClinicalTrials.gov (online). 2011. http://​www.​clinicaltrials.​gov. Accessed 13 Nov 2012.
46.
Novo Nordisk. Comparison of NN1250 versus insulin glargine in subjects with type 2 diabetes (BEGIN™) [ClinicalTrials.gov identifier NCT01059799]. US National Institutes of Health, ClinicalTrials.gov (online). 2011. http://​www.​clinicaltrials.​gov. Accessed 13 Nov 2012.
47.
Novo Nordisk. Comparison of NN1250 with insulin glargine in subjects with type 2 diabetes (BEGIN™) [ClinicalTrials.gov identifier NCT01068665]. US National Institutes of Health, ClinicalTrials.gov (online). 2011. http://​www.​clinicaltrials.​gov. Accessed 15 Nov 2012.
48.
Freemantle N, Meneghini L, Christensen T, et al. Insulin degludec improves health-related quality of life (SF-36®) compared with insulin glargine in people with type 2 diabetes starting on basal insulin: a meta-analysis of phase 3a trials. Diabet Med. 2013;30(2):226–32.PubMedCrossRef
49.
Heise T, Tack CJ, Cuddihy R, et al. A new-generation ultra-long-acting basal insulin with a bolus boost compared with insulin glargine in insulin-naïve people with type 2 diabetes: a randomized, controlled trial. Diabetes Care. 2011;34(3):669–74.PubMedCrossRef
50.
Nakamura S, Ono Y, Rabøl R, et al. Superior glycaemic control with once-daily IDegAsp vs insulin glargine in Japanese adults with type 2 diabetes mellitus inadequately controlled with OADs: a randomised controlled, phase 3 trial [abstract no. 949]. Diabetologia. 2012;55(Suppl 1):S390.
51.
Niskanen L, Leiter LA, Franek E, et al. Comparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trial. Eur J Endocrinol. 2012;167(2):287–94.PubMed
52.
Novo Nordisk. Comparison of NN5401 with insulin glargine in insulin naive subjects with type 2 diabetes (BOOST™) [ClinicalTrials.gov identifier NCT01272193]. US National Institutes of Health, ClinicalTrials.gov (online). 2012. http://​www.​clinicaltrials.​gov. Accessed 15 Nov 2012.
53.
54.
Ratner R, Gough SCL, Mathieu C, et al. Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: pre-planned meta-analysis of phase 3 trials. Diabetes Obes Metab. 2013;15(2):175–84.PubMedCrossRef
55.
Muggeo M, Verlato G, Bonora E, et al. Long-term instability of fasting plasma glucose, a novel predictor of cardiovascular mortality in elderly patients with non-insulin-dependent diabetes mellitus: the Verona Diabetes Study. Circulation. 1997;96(6):1750–4.PubMedCrossRef
56.
57.
Wakil A, Atkin SL. Efficacy and safety of ultra-long-acting insulin degludec. Ther Adv Endocrinol Metab. 2012;3(2):55–9.PubMedCrossRef
58.
American Diabetes Association Workgroup on Hypoglycemia. Defining and reporting hypoglycaemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care. 2005;28(5):1245–9.CrossRef
59.
60.
Tahrani AA, Bailey CJ, Barnett AH. Insulin degludec: a new ultra-longacting insulin. Lancet. 2012;379(9825):1465–7.PubMedCrossRef
61.
Keating GM. Insulin detemir: a review of its use in the management of diabetes mellitus. Drugs. 2012;72(17):2255–87.PubMedCrossRef
62.
63.
64.
65.
Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. Diabetes Care. 2010;33(7):1674–85.PubMedCrossRef
66.
Dejgaard A, Lynggaard H, Råstam J, et al. No evidence of increased risk of malignancies in patients with diabetes treated with insulin detemir: a meta-analysis. Diabetologia. 2009;52(12):2507–12.PubMedCrossRef
67.
Evans M, Schumm-Draeger PM, Vora J, et al. A review of modern insulin analogue pharmacokinetic and pharmacodynamic profiles in type 2 diabetes: improvements and limitations. Diabetes Obes Metab. 2011;13(8):677–84.PubMedCrossRef
68.
Gerstein HC, Bosch J, Dagenais GR, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012;367(4):319–28.PubMedCrossRef
69.
Wang F, Surh J, Kaur M. Insulin degludec as an ultralong-acting basal insulin once a day: a systematic review. Diabetes Metab Syndr Obes. 2012;5:191–204.PubMedCrossRef
Metadaten
Titel
Insulin Degludec and Insulin Degludec/Insulin Aspart: A Review of Their Use in the Management of Diabetes Mellitus
verfasst von
Gillian M. Keating
Publikationsdatum
01.05.2013
Verlag
Springer International Publishing AG
Erschienen in
Drugs / Ausgabe 6/2013
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI
https://doi.org/10.1007/s40265-013-0051-1

Weitere Artikel der Ausgabe 6/2013

Drugs 6/2013 Zur Ausgabe

Leading Article

Using Multiple Targeted Therapies in Oncology: Considerations for Use, and Progress to Date in Breast Cancer

R&D Insight Report

Pomalidomide: First Global Approval

Review Article

Re-examination of Maintenance Therapy in Non-Small Cell Lung Cancer with the Advent of New Anti-cancer Agents

Review Article

Cytochrome P450-Mediated Changes in Oxycodone Pharmacokinetics/Pharmacodynamics and Their Clinical Implications

Systematic Review

Identification and Assessment of Adherence-Enhancing Interventions in Studies Assessing Medication Adherence Through Electronically Compiled Drug Dosing Histories: A Systematic Literature Review and Meta-Analysis

R&D Insight Report

Ospemifene: First Global Approval